The Swiss drug manufacturer Roche closed the first quarter of 2024 with sales increased by 2% CER (-6% in CHF) a 14.4 billion francs as strong demand for newer drugs and diagnostic products including immunodiagnostics, clinical chemistry tests and advanced staining solutions more than offset expected COVID-19-related sales declines and the impact of biosimilar/generic erosion .
After this quarter, the impact of sales declines related to COVID-19 will be largely overcome and there will be no further substantial impact on Group sales. Excluding COVID-19 related products, sales increased 7%.
“We had a happy start to the yearwith both our divisions reporting high single-digit growth in their core business, excluding COVID-19 related sales – commented Thomas Schinecker, CEO by Roche – After this quarter, the impact of COVID-19 on sales is largely behind us. The appreciation of the Swiss franc against most currencies has impacted sales reported in Swiss francs compared to the same period last year.”
“We are confident of growing our Group’s sales in the mid-single digits this year (at constant exchange rates) and therefore we confirm our perspectives for 2024,” he added.
Tags: Roche #1st quarter sales due exchange rate effect COVID
